Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Audentes Therapeutics, Inc. (NASDAQ: BOLD).

Full DD Report for BOLD

You must become a subscriber to view this report.


Recent News from (NASDAQ: BOLD)

Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , Dec. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted ...
Source: PR Newswire
Date: December, 07 2018 18:00
Audentes down 21% after Q3 report and pipeline update
Audentes Therapeutics ( BOLD -21.3% ) slumps on a 4x surge in volume after its Q3 report and business update released after the close yesterday. Key events/milestones: More news on: Audentes Therapeutics, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 12:06
Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it w...
Source: PR Newswire
Date: November, 07 2018 08:00
Audentes Therapeutics (BOLD) CEO Matt Patterson on Q3 2018 Results - Earnings Call Transcript
Audentes Therapeutics (BOLD) Q3 2018 Earnings Conference Call November 6, 2018 04:30 PM ET Executives Matt Patterson - President and CEO Tom Soloway - SVP and CFO Natalie Holles - President and COO Suyash Prasad - SVP and CMO Andrew Chang - Director of IR Analysts Ritu ...
Source: SeekingAlpha
Date: November, 06 2018 23:14
Audentes Therapeutics misses by $0.09
Audentes Therapeutics (NASDAQ: BOLD ): Q3 GAAP EPS of -$0.97 misses by $0.09. More news on: Audentes Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 16:11
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SAN FRANCISCO , Nov. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financ...
Source: PR Newswire
Date: November, 06 2018 16:01
Notable earnings after Tuesday's close
ACAD , AAXN , AIZ , APEI , ASH , BEL , BOLD , BWXT , CHUY , COHR , CPE , CSLT , CUTR , CWH , DAR , DATA , DIOD , DK , DOOR , DPLO , DVN , DXC , DXCM , EGN , ENLC , ENLK , ENPH , ETSY , EVH , EVRI , FANG , FIVN , FTK , FTR , G , GDDY , GHDX , GLUU , HAL...
Source: SeekingAlpha
Date: November, 05 2018 17:35
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
SAN FRANCISCO , Nov. 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-F...
Source: PR Newswire
Date: November, 05 2018 08:00
Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018
SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference c...
Source: PR Newswire
Date: October, 30 2018 08:00
Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo - Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Ensign Group, Inc. (NASDAQ:ENSG), Forterra, Inc. (NASDAQ:FRTA), ...
Source: GlobeNewswire
Date: October, 16 2018 07:36

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1323.8622.9423.9622.7742319,285
2018-12-1223.8223.6823.98523.52235,401
2018-12-1123.7823.4824.6823.18278,408
2018-12-1023.5323.3223.6922.61491,664
2018-12-0723.9523.4424.38522.71533,038

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1314,855159,5049.3132Cover
2018-12-127,79950,75915.3648Cover
2018-12-1119,492100,85819.3262Cover
2018-12-1013,998249,1105.6192Cover
2018-12-0741,670206,39120.1898Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BOLD.


About Audentes Therapeutics, Inc. (NASDAQ: BOLD)

Logo for Audentes Therapeutics, Inc. (NASDAQ: BOLD)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,254,258,563 - 05/11/2018
  • Issue and Outstanding: 36,674,227 - 03/05/2018

 


Recent Filings from (NASDAQ: BOLD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 23 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018

 

 


Daily Technical Chart for (NASDAQ: BOLD)

Daily Technical Chart for (NASDAQ: BOLD)


Stay tuned for daily updates and more on (NASDAQ: BOLD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BOLD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BOLD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BOLD and does not buy, sell, or trade any shares of BOLD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/